Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

JPMorgan Chase & Co. upgraded shares of BioNTech from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $91.00 to $125.00 in a research note on ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

JPMorgan Chase & Co. upgraded BioNTech from an underweight rating to a neutral rating and increased their price objective for the stock from $91.00 to $125.00 in a research report on Monday ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Revenues for both companies shot through the roof, as did their stock prices. But three years later, times have changed dramatically for both companies. On Aug. 9, 2021, BioNTech hit an all-time ...

The revised price target reflects the company's near-term revenue ... as they could potentially enhance the company's position in the cancer treatment market. BioNTech's stock performance will likely ...

TD Cowen has maintained a Hold rating on BioNTech (NASDAQ: NASDAQ:BNTX), while increasing the stock's price target to $132 from $85. The adjustment reflects an updated financial model projecting ...

TD Cowen has maintained a Hold rating on BioNTech (NASDAQ: NASDAQ:BNTX), while increasing the stock's price target to $132 from $85. The adjustment reflects an updated financial model projecting ...